secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vericel Corp (VCEL)
CIK:        0000887359
Form:       8-K
Filed at:   2024-08-26T23:59:59+00:00
Accession:  0001140361-24-038472
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Vericel's MACI Arthro for arthroscopic knee cartilage repair
-------------------------------------------------------------------------

- FDA approved sBLA for arthroscopic delivery of MACI (MACI Arthro) to repair knee defects up to 4 cm².
- MACI Arthro targets largest segment of $3B addressable market: ~20,000 patients/year with 2-4 cm² femoral condyle defects.
- Vericel expanding target surgeon base from 5,000 to 7,000 to include high-volume arthroscopic cartilage repair surgeons.
- MACI is first FDA-approved cellularized scaffold and first restorative biologic approved for arthroscopic administration.
- CEO Nick Colangelo: approval supports sustained top-tier revenue growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/887359/000114036124038472/0001140361-24-038472-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/887359/000114036124038472/ef20034807_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-038472

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer